Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million. Bluebird said late Friday that Ayrmid made ...

Bluebird bio shares were 23% higher, at $5.03, after the company said it received an unsolicited, non-binding written acquisition proposal from Ayrmid. Ayrmid has offered to buy bluebird for an ...